LivaNova (LIVN)

• Market cap: $3.06B
• 1 day: -0.57%
• 5 days: 4.91%
• 1 month: 28.92%
• 3 months: 27.28%
• 6 months: 35.17%
• Year to date: 20.11%
• 1 year: 20.16%
• 5 years: 22.39%
• 10 years: -19.88%
• Sector: Healthcare
• Industry: Medical Devices

About: UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Employees: 2,900

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

30% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 79

16% more capital invested

Capital invested by funds: $2.11B [Q1] → $2.44B (+$329M) [Q2]

14% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 36

0.45% more ownership

Funds ownership: 98.75% [Q1] → 99.2% (+0.45%) [Q2]

0% more funds holding

Funds holding: 248 [Q1] → 248 (+0) [Q2]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.53M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $58 4% upside
• Avg. target: $58 4% upside
• High target: $58 4% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Barclays Matt Miksic

4% upside $58

Equal-Weight Maintained

21 Aug 2025